NCT00655252No Longer Available不适用
An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 40
研究概览
简要总结
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (40)
Loading locations...
相似试验
已完成
3 期
Expanded Access Program for Maraviroc At Multiple CentersHIV InfectionsNCT00426660ViiV Healthcare1,047
Available
不适用
Expanded Access Program for GBM SubjectsGlioblastomaNCT06676891Rznomics, Inc.
Approved For Marketing
不适用
Olaratumab (LY3012207) Patient Access for Soft Tissue SarcomaSoft Tissue SarcomaNCT03994627Eli Lilly and Company
已完成
4 期
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCarcinoma, Large CellNeuroendocrine TumorsNCT01317615Novartis Pharmaceuticals49
已完成
4 期
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)Neuroendocrine TumorsNCT01595009Novartis Pharmaceuticals246